PE firm ChrysCapital acquires Swiss parent's stake in Novartis India

PE firm ChrysCapital acquires Swiss parent's stake in Novartis India

ChrysCapital acquires a 70.68% stake in Novartis India in a ₹1,446 crore deal, appoints new leadership and targets growth in branded generics.

ChrysCapital completes acquisition of an Indian subsidiary of a global pharma company

ChrysCapital, one of the biggest private equity firms investing in India, acquired a controlling 70.68% stake in Novartis India Limited (NIL). The transaction marks a defining moment for ChrysCapital and for the Indian pharmaceutical sector bringing one of India’s longstanding pharmaceutical businesses under dedicated private equity ownership, with the ambition to build a leading branded-generics platform for the Indian market. NIL has a legacy …